Protara Therapeutics, Inc. SEC filings TARA
Protara Therapeutics, Inc. has 809 filings in SEC EDGAR's recent list, going back to Apr 14, 2006. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 11, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEF 14A | Proxy statement | Apr 28, 2026 | Jun 12, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2026 | Apr 17, 2026 |
| DEFA14A | Additional proxy material | Apr 25, 2025 | — |
| DEF 14A | Proxy statement | Apr 25, 2025 | Jun 11, 2025 |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 7, 2024 |
| DEFA14A | Additional proxy material | Apr 26, 2023 | — |
| DEF 14A | Proxy statement | Apr 26, 2023 | Jun 7, 2023 |
| DEFA14A | Additional proxy material | Apr 27, 2022 | — |
| DEF 14A | Proxy statement | Apr 27, 2022 | Jun 8, 2022 |
| DEFA14A | Additional proxy material | Apr 27, 2021 | — |
| DEF 14A | Proxy statement | Apr 27, 2021 | Jun 9, 2021 |
| DEFA14A | Additional proxy material | Apr 23, 2020 | — |
| DEF 14A | Proxy statement | Apr 23, 2020 | Jun 9, 2020 |
| DEF 14A | Proxy statement | Apr 26, 2018 | Jun 8, 2018 |
| DEF 14A | Proxy statement | Jul 13, 2017 | Jul 31, 2017 |
| PRE 14A | Preliminary proxy statement | Jun 30, 2017 | Jun 30, 2017 |
| DEFA14A | Additional proxy material | Jun 23, 2017 | — |
| DEFA14A | Additional proxy material | Jun 22, 2017 | — |
| DEF 14A | Proxy statement | Apr 27, 2017 | Jun 20, 2017 |
| DEF 14A | Proxy statement | Apr 20, 2016 | Jun 9, 2016 |
| DEF 14A | Proxy statement | Apr 21, 2015 | Jun 2, 2015 |
Showing 23 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TARA (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1359931
- Former names
- Protara Therapeutics, Inc. (until Aug 13, 2026); ArTara Therapeutics, Inc. (until Apr 23, 2020); PROTEON THERAPEUTICS INC (until Dec 31, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.